1. To determine the feasibility and toxicity of employing allogeneic peripheral blood stem
cell transplantation after intensive but non-myeloablative chemotherapy in patients with
relapsed Hodgkin's disease (HD).
2. To determine the engraftment kinetics and degree of chimerism that can be achieved with
this strategy.
3. To assess the antitumor activity of this approach in high-risk HD patients and the
possible presence of a graft-vs-HD effect.